How to Treat Metastatic NSCLC with Targetable Mutations – Treatment Algorithm with Dr. Eric Singhi

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the exciting world of metastatic non-small cell lung cancer (NSCLC) with a focus on targeted mutations in the frontline setting.   We were joined by Dr. Eric Singhi from MD Anderson Cancer Center, to discuss the latest advancements in treatment options, including: Common EGFR mutations and the benefits of combination therapies over single-agent osimertinib. The role of CNS involvement in treatment decisions and the importance of patient-centered care. Strategies for managing disease progression and the significance of re-biopsy. Insights into ALK-positive disease, including the efficacy of lorlatinib and alectinib. The latest developments in treating rare mutations like NTRK, MET, RET, and HER2. With a wealth of clinical data and practical insights, this episode is packed with valuable information for oncologists and healthcare professionals. Tune in to learn how to navigate the complexities of NSCLC treatment and improve patient outcomes.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://twitter.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to subscribe for more discussions on oncology topics and share your thoughts in the comments below! #LungCancer, #TargetedTherapy, #PrecisionMedicine, #NGS, #OncologyBrothers